TABLE OF CONTENTS
1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.3 OVERVIEW OF NORTH AMERICA BLOOD SCREENING MARKET 29
1.4 CURRENCY AND PRICING 30
1.5 LIMITATION 31
1.6 MARKETS COVERED 31
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHIC SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 CURRENCY AND PRICING 37
2.5 RESEARCH METHODOLOGY 38
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
2.7 DBMR MARKET POSITION GRID 42
2.8 THE CATEGORY VS TIME GRID 43
2.9 THE CATEGORY VS TIME GRID 44
2.10 DBMR MARKET CHALLENGE MATRIX 45
2.11 SECONDARY SOURCES 46
2.12 ASSUMPTIONS 46
3 MARKET OVERVIEW 47
3.1 DRIVERS 49
3.1.1 RISE IN THE DEMAND OF BLOOD DONATIONS AND BLOOD DONORS 49
3.1.2 RISING PREVALENCE IN NUMBER OF DISEASES 49
3.1.3 RISING NUMBER OF INITIATIVES BY VARIOUS GOVERNMENTS AND GOVERNMENT ASSOCIATIONS 50
3.2 RESTRAINTS 51
3.2.1 LACK OF USING NAT TECHNLOGY IN EMERGING COUNTRIES 51
3.2.2 HIGH COST OF TECHNOLOGY AND INSTRUMENTS 51
3.2.3 EMERGING ALTERNATIVE TECHNOLOGIES 52
3.3 OPPORTUNITIES 53
3.3.1 INCREASING MICROBIOLOGY SCREENING & MULTIPLEXING 53
3.4 CHALLENGES 54
3.4.1 REDUCTION IN PRICE FOR TECHNOLOGY AND INSTRUMENT 54
4 EXECUTIVE SUMMARY 55
5 PREMIUM INSIGHTS 59
6 NORTH AMERICA BLOOD SCREENING MARKET, BY PRODUCTS & SERVICES 61
6.1 OVERVIEW 62
6.2 REAGENTS & KITS 64
6.2.1 ELISA REAGENTS & KITS 66
6.2.1.1 IMMUNOSORBENTS 67
6.2.1.2 CONJUGATES 67
6.2.1.3 SUBSTRATES 67
6.2.1.4 CONTROLS 67
6.2.1.5 SAMPLE DILUENTS AND WASH SOLUTIONS 67
6.2.2 NAT REAGENTS & KITS 67
6.2.2.1 PROBES AND PRIMERS 68
6.2.2.2 ENZYMES AND POLYMERASES 68
6.2.2.3 LABELING AND DETECTION REAGENTS 68
6.2.2.4 STANDARDS AND CONTROLS 68
6.2.2.5 BUFFERS, NUCLEOTIDES AND SOLUTIONS 68
6.3 INSTRUMENTS 69
6.3.1.1 INSTRUMENTS, PRODUCT TYPE 70
6.3.1.1.1 SEMI AUTOMATED 70
6.3.1.1.2 AUTOMATED 70
6.3.1.2 INSTRUMENTS, PURCHASE TYPE 70
6.3.1.2.1 OUTRIGHT PURCHASE 70
6.3.1.2.2 RENTAL 70
6.4 SOFTWARE & SERVICES 71
7 NORTH AMERICA BLOOD SCREENING MARKET, BY TECHNOLOGY 72
7.1 OVERVIEW 73
7.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 75
7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY PLATFORM 77
7.2.1.1 COLORIMETRIC IMMUNOASSAY (CI) 77
7.2.1.2 CHEMILUMINESCENCE IMMUNOASSAY (CLIA) 77
7.2.1.3 FLUORESCENCE IMMUNOASSAY (FIA) 77
7.2.2 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY GENERATIONS 77
7.2.2.1 FIRST-GENERATION ELISA 77
7.2.2.2 SECOND-GENERATION ELISA 77
7.2.2.3 THIRD-GENERATION ELISA 77
7.2.2.4 FOURTH-GENERATION ELISA 77
7.3 RAPID TESTS 78
7.4 NEXT-GENERATION SEQUENCING (NGS) 79
7.5 NUCLEIC ACID TEST 80
7.5.1 REAL-TIME POLYMERASE CHAIN REACTION (PCR) 81
7.5.2 TRANSCRIPTION-MEDIATED AMPLIFICATION (TMA) 81
7.6 WESTERN BLOT ASSAY 82
7.7 OTHERS 83
8 NORTH AMERICA BLOOD SCREENING MARKET, BY DISEASE TYPE 84
8.1 OVERVIEW 85
8.2 ONCOLOGY 87
8.3 DIABETES MELLITUS 88
8.4 COLD & FLU 89
8.5 CHOLESTEROL 90
8.6 INFECTIOUS DISEASES 91
8.7 RESPIRATORY DISEASES 92
8.8 HIV/AIDS 93
8.9 OTHERS 94
9 NORTH AMERICA BLOOD SCREENING MARKET, BY END USER 95
9.1 OVERVIEW 96
9.2 DIAGNOSTIC CENTERS 98
9.3 BLOOD BANK 99
9.4 HOSPITALS 100
9.5 CLINICS 101
9.6 AMBULATORY SURGICAL CENTERS 102
10 NORTH AMERICA BLOOD SCREENING MARKET, BY GEOGRAPHY 103
10.1 NORTH AMERICA 103
10.1.1 U.S. 114
10.1.2 CANADA 121
10.1.3 MEXICO 128
11 NORTH AMERICA BLOOD SCREENING MARKET, COMPANY LANDSCAPE 135
11.1 COMPANY SHARE ANALYSIS; NORTH AMERICA 135
12 COMPANY PROFILES 136
12.1 F. HOFFMANN-LA ROCHE LTD 136
12.1.1 COMPANY OVERVIEW 136
12.1.2 REVENUEANALYSIS 136
12.1.3 COMPANY SHARE ANALYSIS 137
12.1.4 PRODUCT PORTFOLIO 137
12.1.5 RECENT DEVELOPMENT 138
12.2 ABBOTT 139
12.2.1 COMPANY OVERVIEW 139
12.2.2 REVENUE ANALYSIS 139
12.2.3 COMPANY SHAREV ANALYSIS 140
12.2.4 PRODUCT PORTFOLIO 140
12.2.5 RECENT DEVELOPMENT 141
12.3 THERMO FISHER SCIENTIFIC INC. 142
12.3.1 COMPANY OVERVIEW 142
12.3.2 REVENUE ANALYSIS 142
12.3.3 COMPANY SHAREV ANALYSIS 143
12.3.4 PRODUCT PORTFOLIO 143
12.3.5 RECENT DEVELOPMENTS 144
12.4 SIEMENS AG 145
12.4.1 COMPANY OVERVIEW 145
12.4.2 REVENUE ANALYSIS 145
12.4.3 COMPANY SHAREV ANALYSIS 146
12.4.4 PRODUCT PORTFOLIO 146
12.4.5 RECENT DEVELOPMENTS 148
12.5 BIO-RAD LABORATORIES, INC. 149
12.5.1 1.3.1COMPANY OVERVIEW 149
12.5.2 REVENUE ANALYSIS 149
12.5.3 COMPANY SHAREV ANALYSIS 150
12.5.4 PRODUCT PORTFOLIO 150
12.5.5 RECENT DEVELOPMENTS 152
12.6 BD 153
12.6.1 COMPANY OVERVIEW 153
12.6.2 REVENUE ANALYSIS 153
12.6.3 PRODUCT PORTFOLIO 154
12.6.4 RECENT DEVELOPMENTS 154
12.7 BECKMAN COULTER, INC. 155
12.7.1 COMPANY OVERVIEW 155
12.7.2 GEOGRAPHICPRESENCE 155
12.7.3 PODUCT PORTFOLIO 156
12.7.4 RECENET DEVELOPEMENTS 157
12.8 BIOM?RIEUX SA 158
12.8.1 COMPANY OVERVIEW 158
12.8.2 REVENUE ANALYSIS 158
12.8.3 PRODUCT PORTFOLIO 159
12.8.4 RECENT DEVELOPMENT 160
12.9 CEPHEID (A SUBSIDIARY OF DANAHER CORPORATION) 161
12.9.1 COMPANY OVERVIEW 161
12.9.2 GEOGRAPHIC PRESENCE 161
12.9.3 PRODUCT PORTFOLIO 162
12.9.4 RECENT DEVELOPMENT 163
12.10 ENZO BIOCHEM INC. 164
12.10.1 COMPANY OVERVIEW 164
12.10.2 REVENUE ANALYSIS 164
12.10.3 PRODUCT PORTFOLIO 165
12.10.4 RECENT DEVELOPMENTS 166
12.11 GRIFOLS INTERNATIONAL, S.A. 167
12.11.1 COMPANY OVERVIEW 167
12.11.2 REVENUE ANALYSIS 167
12.11.3 PRODUCT PORTFOLIO 168
12.11.4 RECENT DEVELOPMENTS 169
12.12 HOLOGIC INC. 170
12.12.1 COMPANY OVERVIEW 170
12.12.2 REVENUE ANALYSIS 170
12.12.3 PRODUCT PORTFOLIO 171
12.12.4 RECENT DEVELOPMENTS 171
12.13 IMMUCOR, INC. 172
12.13.1 COMPANY OVERVIEW 172
12.13.2 GEOGRAPHIC PRESENCE; 172
12.13.3 PRODUCT PORTFOLIO 173
12.13.4 RECENT DEVELOPMENTS 174
12.14 MERIDIAN BIOSCIENCE, INC. 175
12.14.1 COMPANY OVERVIEW 175
12.14.2 REVENUE ANALYSIS 175
12.14.3 PRODUCT PORTFOLIO 176
12.14.4 RECENT DEVELOPMENTS 177
12.15 ORTHO CLINICAL DIAGNOSTICS 178
12.15.1 COMPANY OVERVIEW 178
12.15.2 GEOGRAPHIC PRESENCE 178
12.15.3 PRODUCT PORTFOLIO 179
12.15.4 RECENT DEVELOPMENTS 180
13 RELATED REPORTS 181